DUBLIN–(BUSINESS WIRE)–The “Oral Mucositis (OM) – Market Insight, Epidemiology and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
The OM market report provides current treatment practices, emerging drugs, OM market share of the individual therapies, current and forecasted OM market size from 2018 to 2030 segmented by seven major markets. The Report also covers current OM treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
OM Epidemiology
The OM epidemiology division provides the insights about historical and current OM patient pool and forecasted trends for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018-2030.
The disease epidemiology covered in the report provides historical as well as forecasted OM epidemiology segmented as [Total Incident Cases of OM, Grade-specific cases of OM, and Treated cases of OM] scenario of OM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Country Wise- OM Epidemiology
- Estimates show that the highest incident cases of OM in the 7MM were in the United States, followed by Japan in 2020.
- The United States, in 2020, accounted for 596,671, OM incident cases, which are expected to grow during the study period, i.e., 2018-2030.
- In the year 2020, the total incident cases of OM in EU5 were 623,424, which are expected to grow during the study period, i.e., 2018-2030.
- In the year 2020, the total incident cases of OM in Japan were 260,358, which are expected to grow during the study period, i.e., 2018-2030.
OM Approved Drugs/Devices
Kepivance/palifermin (Amgen/ Swedish Orphan Biovitrum)
Kepivance (palifermin) is a truncated human keratinocyte growth factor (KGF) produced by recombinant DNA technology in E coli. It is a medicine indicated for the prevention and treatment of severe oral mucositis (mouth sores). It is used in patients with certain forms of blood cancer who are undergoing high-dose chemotherapy accompanied by a stem cell transplant and radiation therapy. The prevention and treatment of common side effects of other cancer types are also being studied.
MuGard (Access Pharmaceuticals (now Abeona Therapeutics)
MuGard is a mucoadhesive oral wound rinse Rinse is a viscous hydrogel polymer solution that is dispensed in a ready-to-use form. This device is supplied in plastic bottles is intended for the treatment of oral wounds such as mucositis, stomatitis, traumatic ulcers, and aphthous ulcers. The mucoadhesive formulation results in the development of a protective coating over the oral mucosa when swirled carefully across the mouth. Patients should use MuGard 4 to 6 times daily, 5 mL of ready-to-use MuGard coats the oral cavity, and up to 10 mL can be used if needed.
Chemo Mouthpiece (Chemo Mouthpiece/Aurora BioScience)
Chemo Mouthpiece is a discreet, secure, and easy-to-use cryotherapy device that can effectively mitigate the debilitating effects of chemotherapy-induced oral mucositis. Chemo Mouthpiece builds upon an established treatment form, cryotherapy, which uses cold temperatures to improve the condition of the body. It is the same strategy that introduced ice chips and popsicles to hospitals and infusion centers. The device includes two chambers, a center core filled with filtered water, and an outer section filled with proprietary saline, which can reach freezing temperatures without solidifying. Two tubes run through the device so the patient can breathe comfortably. Chemo Mouthpiece can help battle the worst of the symptoms of oral mucositis by limiting the number of toxic chemicals that can interfere with the tissues of the cheeks, gums, tongue, lips, and palate.
Episil (Camurus)
Episil is a lipid-based fluid that transforms into a thin bioadhesive film when in contact with the buccal membrane, alleviating pain by protecting mucous membranes. In clinical trials, episil has been proven to reduce pain in the mouth by up to 40%, with a long-lasting effect of up to eight hours. The outstanding features of Episil are that it provides instant relief that is within five minutes post-application, in addition to this, it is convenient to consume food and drink within the same time only, and it acts as an effective oral pain relief lasting up to eight hours that comes handy with a ready-to-use, pocket-sized device.
OM Market Outlook
Currently, clinical management of oral mucositis is largely focused on palliative measures such as pain management, nutritional support, and maintenance of good oral hygiene. Recombinant human keratinocyte growth factor-1 (Palifermin) reduces the incidence of WHO grade 3 and 4 oral mucositis in patients with hematologic malignancies (e.g. lymphoma and multiple myeloma) receiving high-dose chemotherapy and total body irradiation before autologous hematopoietic cell transplantation.
The US FDA has also approved Palifermin for patients with hematologic malignancies receiving myelotoxic therapies requiring hematopoietic cell support. The other treatment options may include interventions to reduce the mucosal toxicity of chemotherapy drugs, mouthwashes, immunomodulatory agents, topical anesthetics, mucosal barriers and coating agents, cytoprotectants.
OM Pipeline Development Activities
The drugs/devices which are in pipeline include:
1. Avasopasem/GC4419 (Galera Therapeutics)
2. SGX942 (Soligenix)
3. CareMin650 (NeoMedLight)
4. Cooral/CoolPrevent (BrainCool)
Companies Mentioned
- Access Pharmaceuticals
- Amgen/ Swedish Orphan Biovitrum
- BrainCool
- Camurus
- Chemo Mouthpiece/ Aurora BioScience
- Enzychem Lifesciences Corporation
- EpicentRx/Prothex Pharma
- Innovation Pharmaceuticals
- Monopar Therapeutics
- MuReva (Lumitex)
- NeoMedLight
- Soligenix
For more information about this report visit https://www.researchandmarkets.com/r/xftd37
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900